The Experimental Medicine and Immunotherapeutics division has a strong record in clinical research. Our interests are mainly in the field of hypertension and cardiovascular medicine. The clinical trials are run from Level 3 of the Addenbrooke’s Centre for Clinical Investigation (ACCI) from the Clinical Investigation Ward and the Vascular Research Clinics. We run large-scale clinical trials looking at drug therapy in hypertension as well as longitudinal collaborative studies investigating novel risk factors for cardiovascular disease. Past examples of physiological and interventional clinical trials include the AngloCardiff Collaborative Trial (ACCT) studies, PEXIVAS, RITAZAREM and ALEVIATE studies. We are increasingly using imaging modalities such as PET-CT and MRI to understand and characterise cardiovascular conditions such as vascular inflammation, adrenal function and arterial stiffness. We use a number of non-invasive techniques to look at vascular and endothelial function. Some information about PIs interested in clinical research is in the table below. More information about our interests in clinical research may also be found under individual PI pages. Also listed below is a brief summary of current clinical trials / studies within the EMIT Unit. We are also closely associated with the new Cambridge University Health Partners’ Clinical Trials Unit, with one of our PIs being its Director.
Professor Ian Wilkinson : Director of the new Cambridge University Health Partners’ Clinical Trials Unit. Research interests in physiology and pharmacology of the cardiovascular system, in particular the large arteries.
Dr Joseph Cheriyan : Director of the Cardiovascular Clinical Trials Office, Cambridge University Hospitals & Vice Chair, Cambridge Central Ethics Committee. Clinical trials / studies to investigate the role of novel therapeutic agents on vascular function.
Professor David Jayne : Director of the Vasculitis and Lupus Service, Addenbrooke’s Hospital
Dr Carmel McEniery : Detailed physiological phenotyping of the cardiovascular system to understand the factors regulating blood pressure and vascular function in health and disease.
Current EMIT Clinical Research Studies / Trials
|AIM HY - INFORM
ASPIRE is a physiological study at Cambridge University Hospitals sponsored by Cambridge University Hospitals NHS Foundation Trust. The aim of the study is to evaluate whether low dose aspirin and omega-3 supplementation impacts resolution mediators measured in blood samples in people with COPD or smokers and healthy volunteers without COPD who are never smokers.
Influence of Age, Weight and Ethnic background on blood pressure
Identifying vascular Calcification and inflammation in patients witH end-stage renAL disease by PET CT and protein biomarKers
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin (DEFINE)
Evaluation of nitric oxide and catecholamine sensitivity in patients with autonomic neuropathy.
|Endothelial Dysfunction in Renal Transplantation
Does receiving a kidney transplant stimulate the immune system which then contributes to endothelial dysfunction?
Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mab Inhibitor (alirocumab) in healthy volunteers – A mechanistic physiological study
Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease (INTENSITY-HIGH)
The OPACE trial is for people with chronic obstructive pulmonary disease (COPD) who are better than before in their COPD and have been on azithromycin treatment for at least three months to reduce their risk of flare-ups (also called exacerbations). The trial aims to investigate whether compared with continuing azithromycin throughout, can azithromycin be discontinued either completely, or stopped over the summer and restarted in the winter.
A cross-sectional REVEAL sub-study evaluating the effect of anacetrapib on vascular function and arterial stiffness
The Preconception to pOst-partum study of cardiometabolic health in Primigravid PregnancY Study (POPPY) aims to understand more about the risks of developing heart disease and diabetes in women who experienced placental complications such as pre-eclampsia (high blood pressure and kidney problems), high blood pressure during pregnancy and fetal growth restriction (baby being small). We hope that by understanding these risks we can improve women’s health over their lifetime.
Validation of the Analysis Methodology Behind the Use of Quantitative 18F-FDG PET/CT to Assess Lung Inflammation (VERIFY)